


ANNEXURE A				
Format for Disclosures under Regulation 29(1) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011				
Part-A- Details of the Acquisition				
Name of the Target Company (TC)	ADVANCED ENZYME TECHNOLOGIES LIMITED			
Name(s) of the acquirer and Persons Acting in Concert (PAC) with the acquirer	ORBIMED ASIA III MAURITIUS FVCI LIMITED			
Whether the acquirer belongs to Promoter/Promoter group	NO			
Name(s) of the Stock Exchange(s) where the shares of TC are Listed	BSE & NSE			
Details of the acquisition as follows	Number	% w.r.t. total share/voting capital wherever applicable(*)	% w.r.t. total diluted share/voting capital of the TC (**)	
Before the acquisition under consideration, holding of				
a) Shares carrying voting rights	2,456,277		2.20%	
b) Shares in the nature of encumbrance (pledge/ lien/ non-disposal undertaking/ others)				
c) Voting rights (VR) otherwise than by equity shares				
d) Warrants/convertible securities/any other instrument that entitles the acquirer to receive shares carrying voting rights in the TC (specify holding in each category)				
e) Total (a+b+c)	2,456,277		2.20%	
Details of acquisition				
	a) Shares carrying voting rights acquired	11,053,245		9.88%
	b) VRs acquired otherwise than by equity shares			
c) Warrants/convertible securities/any other instrument				
d) Shares in the nature of encumbrance (pledge/ lien/non-				

e) Total (a+b+c+/-d)	11,053,245		9.88%
<u>After the acquisition, holding of acquirer along with PACs of:</u>			
a) Shares in the nature of encumbrance (pledge/ lien/non-	13,509,522		12.08%
b) VRs otherwise than by equity shares			
c) Warrants/convertible securities/any other instrument			
d) Total (a+b+c)	13,509,522		12.08%
Mode of acquisition (e.g. open market / public issue / rights	PURCHASE ON SECONDARY MARKET		
Salient features of the securities acquired including time till redemption, ratio at which it can be converted into equity			
Date of acquisition of/ date of receipt of intimation of	20-Jun-2024		
Equity share capital / total voting capital of the TC before	111,824,075	(shs)	
Equity share capital/ total voting capital of the TC after the	111,824,075	(shs)	
Total diluted share/voting capital of the TC after the said	111,824,075	(shs)	
Part-B***			
Name of the Target Company: ADVANCED ENZYME TECHNOLOGIES LIMITED			
Name(s) of the acquirer and Persons Acting in Concert (PAC) with the acquirer	Whether the acquirer belongs to Promoter/ Promoter group	PAN of the acquirer and/ or PACs	
ORBIMED ASIA III MAURITIUS FVCI LIMITED	NO		
 Signature of the acquirer / Authorised Signatory Place: Mumbai Date:21-June-2024 Note:			

(*) Total share capital/ voting capital to be taken as per the latest filing done by the company to the Stock Exchange under Clause 35 of the listing Agreement.
(**) Diluted share/voting capital means the total number of shares in the TC assuming full conversion of the outstanding convertible securities/warrants into equity shares of the TC.
(***) Part-B shall be disclosed to the Stock Exchanges but shall not be disseminated.